Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

被引:63
作者
Koeberling, Oliver [1 ]
Seubert, Anja [2 ]
Granoff, Dan M. [1 ]
机构
[1] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA USA
[2] Novartis Vaccines, Siena, Italy
关键词
D O I
10.1086/589308
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Outer membrane vesicle (OMV) vaccines from mutant Neisseria meningitidis strains engineered to overexpress factor H-binding protein (fHbp) have elicited broadly protective serum antibody responses in mice. The vaccines investigated were not treated with detergents to avoid extracting fHbp, which is a lipoprotein. Because of their high endotoxin content, the vaccines would not be safe to administer to humans. Methods. We prepared a native OMV vaccine from a strain engineered to overexpress fHbp and in which the gene encoding LpxL1 was inactivated, which reportedly decreases endotoxin activity. Results. The OMV vaccine from the mutant had a similar or lower ability to induce the expression of proinflammatory cytokines by human peripheral blood mononuclear cells, compared with a detergent-extracted wild-type OMV, and 1000-10,000-fold lower activity than a native wild-type OMV. In mice, the OMV vaccine from the mutant elicited higher serum bactericidal antibody responses to a panel of heterologous N. meningitidis strains than did a control multicomponent recombinant protein vaccine or a detergent-extracted OMV vaccine that has been demonstrated to confer protection against meningococcal disease in humans. Conclusions. The data illustrate the potential to develop a broadly immunogenic native OMV vaccine that has decreased endotoxin activity and is potentially suitable for testing in humans.
引用
收藏
页码:262 / 270
页数:9
相关论文
共 49 条
[1]   Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine [J].
Beernink, Peter T. ;
Welsch, Jo Anne ;
Harrison, Lee H. ;
Leipus, Arunas ;
Kaplan, Sheldon L. ;
Granoff, Dan M. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (10) :1472-1479
[2]   EFFECT OF OUTER-MEMBRANE VESICLE VACCINE AGAINST GROUP-B MENINGOCOCCAL DISEASE IN NORWAY [J].
BJUNE, G ;
HOIBY, EA ;
GRONNESBY, JK ;
ARNESEN, O ;
HOLSTFREDRIKSEN, J ;
HALSTENSEN, A ;
HOLTEN, E ;
LINDBAK, AK ;
NOKLEBY, H ;
ROSENQVIST, E ;
SOLBERG, LK ;
CLOSS, O ;
ENG, J ;
FROHOLM, LO ;
LYSTAD, A ;
BAKKETEIG, LS ;
HAREIDE, B .
LANCET, 1991, 338 (8775) :1093-1096
[3]   Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents [J].
Boutriau, Dominique ;
Poolman, Jan ;
Borrow, Ray ;
Findlow, Jamie ;
Diez Domingo, Javier ;
Puig-Barbera, Joan ;
Baldo, Jose Maria ;
Planelles, Victoria ;
Jubert, Angels ;
Colomer, Julia ;
Gil, Angel ;
Levie, Karin ;
Kervyn, Anne-Diane ;
Weynants, Vincent ;
Dominguez, Francisco ;
Barbera, Ramon ;
Sotolongo, Franklin .
CLINICAL AND VACCINE IMMUNOLOGY, 2007, 14 (01) :65-73
[4]   Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine [J].
Claassen, I ;
Meylis, J ;
vanderLey, P ;
Peeters, C ;
Brons, H ;
Robert, J ;
Borsboom, D ;
vanderArk, A ;
vanStraaten, I ;
Roholl, P ;
Kuipers, B ;
Poolman, J .
VACCINE, 1996, 14 (10) :1001-1008
[5]   NadA, a novel vaccine candidate of Neisseria meningitidis [J].
Comanducci, M ;
Bambini, S ;
Brunelli, B ;
Adu-Bobie, J ;
Aricò, B ;
Capecchi, B ;
Giuliani, MM ;
Masignani, V ;
Santini, L ;
Savino, S ;
Granoff, DM ;
Caugant, DA ;
Pizza, M ;
Rappuoli, R ;
Mora, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (11) :1445-1454
[6]   Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age [J].
de Kleijn, ED ;
de Groot, R ;
Labadie, J ;
Lafeber, AB ;
van den Dobbelsteen, G ;
van Alphen, L ;
van Dijken, H ;
Kuipers, B ;
van Omme, GW ;
Wala, M ;
Juttmann, R ;
Rümke, HC .
VACCINE, 2000, 18 (15) :1456-1466
[7]  
DEMORAES JC, 1992, LANCET, V340, P1074
[8]   Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination [J].
Fisseha, M ;
Chen, P ;
Brandt, B ;
Kijek, T ;
Moran, E ;
Zollinger, W .
INFECTION AND IMMUNITY, 2005, 73 (07) :4070-4080
[9]   Vaccine potential of the Neisseria meningitidis 2086 lipoprotein [J].
Fletcher, LD ;
Bernfield, L ;
Barniak, V ;
Farley, JE ;
Howell, A ;
Knauf, M ;
Ooi, P ;
Smith, RP ;
Weise, P ;
Wetherell, M ;
Xie, XL ;
Zagursky, R ;
Zhang, Y ;
Zlotnick, GW .
INFECTION AND IMMUNITY, 2004, 72 (04) :2088-2100
[10]  
FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67